Abstract
Histological subclassification of non-small cell lung cancer (NSCLC) has growing therapeutic impact. In advanced cancer stages, tissue specimens are usually bioptically collected. These small samples are of extraordinary value since molecular analyses are gaining importance for targeted therapies. We therefore studied the feasibility, diagnostic accuracy, economic and prognostic effects of a tissue-sparing simultaneous multi-antibody assay for subclassification of NSCLC. Of 265 NSCLC patients, tissue multi-arrays (TMA) were constructed to simulate biopsy samples. TMAs were stained by a simultaneous bi-color multi-antibody assay consisting of TTF1, Vimentin, p63 and neuroendocrine markers (CD56, chromogranin A, synaptophysin). Classification was based mainly on the current proposal of the IASLC with a hierarchical decision tree. Investigation of tumor heterogeneity showed an explicit lower variation for immunohistochemical analyses compared to conventional classification. Furthermore, survival analysis of our combined immunohistochemical classification revealed distinct separation of each entity's survival curve (p = 0.045). Our multi-antibody assay delivers accurate and reliable separation of histomorphological diagnoses and permits clinically relevant subtyping of NSCLC including LCNEC, providing substantial prognostic information with therapeutic consequences.
Introduction
In the era of personalized medicine, the precise subclassification of non-small cell lung cancer (NSCLC)—specifically distinguishing between adenocarcinoma (LAC) and squamous cell carcinoma (SCC)—is critical for determining chemotherapy regimens. However, most patients are diagnosed via small needle biopsies. Traditional World Health Organization (WHO) standards rely on large surgical specimens to identify structural patterns. When only limited tissue is available, pathologists must rely on immunohistochemistry (IHC). Running multiple individual IHC tests can quickly exhaust a small sample, leaving insufficient material for essential molecular and genetic analyses. This study addresses the need for a diagnostic method that is accurate, prognostic, and economical with tissue.
Methodology
The researchers developed a simultaneous bi-color multi-antibody assay targeting six markers on a single slide. The assay utilizes a red chromogen (AP-based) for TTF1 (adenocarcinoma marker) and Vimentin (stromal/fixation control), and a brown chromogen (DAB-based) for p63 (squamous marker) and a neuroendocrine cocktail (CD56, Chromogranin A, and Synaptophysin).
Classification followed a hierarchical decision tree. If clear morphological patterns (glands or keratinization) were absent, IHC markers were used: TTF1+ indicated LAC, p63+ indicated SCC, and a positive neuroendocrine (NE) cocktail indicated Large Cell Neuroendocrine Carcinoma (LCNEC). To simulate biopsy conditions, the study used Tissue Microarrays (TMAs) from 265 NSCLC patients, comparing the multi-stain results against "gold standard" diagnoses from full surgical resections.
Key Results
The study demonstrated that IHC markers show significantly less variation across different tumor areas than traditional morphological patterns, making IHC a more reliable tool for small samples. The inclusion of neuroendocrine markers allowed for the identification of LCNEC, a subtype often missed in small biopsies that requires distinct therapeutic approaches.
Key findings include:
- Superior Accuracy: IHC-based classification of small cores showed higher concordance with final surgical diagnosis (Cramer’s V = 0.629) than traditional H&E staining (Cramer’s V = 0.506).
- Prognostic Value: Survival analysis using the IHC classification revealed statistically significant separations between subtype survival curves (p = 0.045), whereas traditional H&E classification failed to provide significant prognostic separation (p = 0.904).
- Efficiency: The assay uses 1/6th of the tissue, reduces reagent costs by 68.8%, and cuts evaluation time by approximately two-thirds compared to individual staining.
Conclusion
Simultaneous multi-antibody staining provides a reliable, tissue-sparing, and cost-effective method for subclassifying NSCLC. By integrating neuroendocrine differentiation into standard classification, this assay delivers critical prognostic information and preserves precious tissue for molecular testing. While prospective studies on clinical biopsies are needed to confirm these findings in real-world workflows, this approach represents a significant advancement in diagnostic pathology for lung cancer.
Summary updated